These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 16443077)

  • 1. An acneiform eruption due to erlotinib: prognostic implications and management.
    Journagan S; Obadiah J
    J Am Acad Dermatol; 2006 Feb; 54(2):358-60. PubMed ID: 16443077
    [No Abstract]   [Full Text] [Related]  

  • 2. Severe acneiform skin reaction during therapy with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor.
    Eames T; Landthaler M; Karrer S
    Eur J Dermatol; 2007; 17(6):552-3. PubMed ID: 17951151
    [No Abstract]   [Full Text] [Related]  

  • 3. Erlotinib-induced pustular eruption.
    Cusano F; Ferrara G; Barletta E; Ingordo V
    G Ital Dermatol Venereol; 2009 Feb; 144(1):93-6. PubMed ID: 19218915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rosaceiform eruption induced by erlotinib.
    Patrizi A; Bianchi F; Neri I
    Dermatol Ther; 2008 Oct; 21 Suppl 2():S43-5. PubMed ID: 18837734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of epidermal growth factor receptor inhibitor-induced acneiform eruption with topical recombinant human epidermal growth factor.
    Shin JU; Park JH; Cho BC; Lee JH
    Dermatology; 2012; 225(2):135-40. PubMed ID: 23006507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acneiform eruption induced by Iressa (gefitinib) tablets used to treat non-small cell lung cancer.
    Warthan MM; Jumper CA; Smith JL
    J Drugs Dermatol; 2004; 3(5):569-70. PubMed ID: 15552613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutaneous adverse effects during therapy with an epidermal growth factor receptor (EGFR) inhibitor.
    Santoro F; Cozzani E; Parodi A
    J Dermatolog Treat; 2006; 17(3):160-1. PubMed ID: 16854757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Scalp pustules in a patient receiving chemotherapy.
    Chiu HY; Chiu HC
    JAMA; 2013 Sep; 310(10):1068-9. PubMed ID: 24026603
    [No Abstract]   [Full Text] [Related]  

  • 9. Description and management of cutaneous side effects during erlotinib and cetuximab treatment in lung and colorectal cancer patients: a prospective and descriptive study of 19 patients.
    de Noronha e Menezes NM; Lima R; Moreira A; Varela P; Barroso A; Baptista A; Parente B
    Eur J Dermatol; 2009; 19(3):248-51. PubMed ID: 19258241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquired trichomegaly and symptomatic external ocular changes in patients receiving epidermal growth factor receptor inhibitors: case reports and a review of literature.
    Zhang G; Basti S; Jampol LM
    Cornea; 2007 Aug; 26(7):858-60. PubMed ID: 17667622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor tyrosine kinase inhibitors induce CCL2 and CCL5 via reduction in IL-1R2 in keratinocytes.
    Yamaki M; Sugiura K; Muro Y; Shimoyama Y; Tomita Y
    Exp Dermatol; 2010 Aug; 19(8):730-5. PubMed ID: 20590818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Erlotinib-induced acneiform rash not affecting previously irradiated skin].
    Eguren C; Domínguez-Fernández I; Santiago-Sánchez-Mateos DI; García-Díez A
    Actas Dermosifiliogr; 2010 Mar; 101(2):186-7. PubMed ID: 20223168
    [No Abstract]   [Full Text] [Related]  

  • 13. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours.
    Jacot W; Bessis D; Jorda E; Ychou M; Fabbro M; Pujol JL; Guillot B
    Br J Dermatol; 2004 Jul; 151(1):238-41. PubMed ID: 15270903
    [No Abstract]   [Full Text] [Related]  

  • 14. Erlotinib-induced skin manifestations.
    Motoki T; Mitsuishi T; Kawana S
    J Dermatol; 2009 Dec; 36(12):658-9. PubMed ID: 19958452
    [No Abstract]   [Full Text] [Related]  

  • 15. Sparing of previously irradiated skin from erlotinib-induced acneiform rash.
    Yalçin S; Dizdar O; Yalçin B; Gököz O
    J Am Acad Dermatol; 2008 Jan; 58(1):178-9. PubMed ID: 18158935
    [No Abstract]   [Full Text] [Related]  

  • 16. Acneiform eruptions induced by epidermal growth factor receptor inhibitors: treatment with oral isotretinoin.
    Requena C; Llombart B; Sanmartín O
    Cutis; 2012 Aug; 90(2):77-80. PubMed ID: 22988651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Follicular drug eruption induced by gefitinib (ZD 1839, iressa): clinical picture correlates with in vitro data of focal epidermal necrosis after epidermal growth factor inhibition in skin cultures.
    Treudler R; Zouboulis CC
    Dermatology; 2005; 211(4):375-6. PubMed ID: 16286753
    [No Abstract]   [Full Text] [Related]  

  • 18. Erlotinib-associated dermatological toxicity.
    Mumoli N; Cei M; Vitale J
    QJM; 2013 Apr; 106(4):363-4. PubMed ID: 22927541
    [No Abstract]   [Full Text] [Related]  

  • 19. A case report of inflammatory nonscarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib.
    Pongpudpunth M; Demierre MF; Goldberg LJ
    J Cutan Pathol; 2009 Dec; 36(12):1303-7. PubMed ID: 19519875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Skin Toxic Effects Associated With Gefitinib, Erlotinib, or Afatinib Treatment for Non-Small Cell Lung Cancer.
    Chen KL; Lin CC; Cho YT; Yang CW; Sheen YS; Tsai HE; Chu CY
    JAMA Dermatol; 2016 Mar; 152(3):340-2. PubMed ID: 26649681
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.